My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
CLARAMUNT-GARCIA, R; MUNOZ-CID, CL and SANCHEZ-RUIZ, A. Tumor lysis syndrome in hematologic patient. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.4, pp.407-409. Epub Oct 23, 2023. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x20220004000017.
Tumor lysis syndrome (TLS) is a life-threatening complication characterized by a massive lysis of tumor cells. The following is the case of a 28-year-old man diagnosed with high-grade B-cell nonHodking lymphoma. The patient presented a TLS after the administration of chemotherapy. This case is of special interest due to the pharmaco logical recommendations proposed by the Pharmacy Service regarding the rasburicasa dose and the interactions at the electrolyte level with the concomitant medication prescribed during admission.
Keywords : Rasburicase; tumor lysis; lymphoma.